American Journal of Preventive Cardiology Publishes Landmark Study on Sex Differences in Homozygous Familial Hypercholesterolemia in First Issue Under New Editor-in-Chief Continue Reading
RIDGEFIELD, Conn., January 28, 2026 – Today, Boehringer Ingelheim and the Detect the SOS Collective, a group of professional organizations, advocates, patients and caregivers, launched a new public health mission: elevate awareness of urine albumin-to-creatinine ratio (uACR) screening to... Continue Reading
Where are cholesterol guidelines headed, and what must the clinical and prevention community do to keep up? Continue Reading
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG) Continue Reading
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) Continue Reading
Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke. Continue Reading
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions. Continue Reading
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations Continue Reading
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment with enlicitide decanoate, an investigational, once-daily oral... Continue Reading
Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month Continue Reading
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the American Heart Association (AHA) Scientific Sessions 2025, taking place in New Orleans. Continue Reading
New Heartflow PCI Navigator to Equip Interventional Cardiologists with Pre-procedural Insights to Enable PCI Planning Continue Reading
